Synektik (SNTP) investor relations material

Executive summary

• Consolidated revenue for 9M FY2025 rose 52% year-over-year to PLN 733.4 million, driven by strong growth in medical equipment and IT solutions sales, as well as maintenance and measurement services.

• EBITDA from continuing operations increased 55% to PLN 189.6 million for 9M FY2025.

• Net profit from continuing operations rose 61% year-over-year to PLN 138.0 million, with total comprehensive income at PLN 386.4 million, including a non-cash gain from the demerger of PLN 261.3 million.

• The Group completed a significant demerger, transferring the cardiotracer project and Center for Research on New Compounds to Syn2bio SA, resulting in a one-time gain and a reduction in equity.

• Significant growth in equipment and IT solutions sales, international expansion, and record contract awards.

Financial highlights

• Q3 FY2025 revenue reached PLN 292.3 million, up 89% year-over-year.

• Q3 FY2025 EBITDA from continuing operations was PLN 71.5 million, up 72% year-over-year.

• Q3 FY2025 net profit from continuing operations rose 80% to PLN 55.1 million.

• Operating profit (EBIT) for the nine months was PLN 173.8 million, up from PLN 107.5 million year-over-year.

• Positive operating cash flow of PLN 141.4 million over 9M FY2025; net cash position of PLN 35.7 million as of June 30, 2026.

Outlook and guidance

• Entered final quarter of 2025 with a backlog and active offers totaling PLN 205 million, a 21% year-over-year increase.

• Preparations underway for launch of operations in Ukraine and commercial launch of Edison system in Poland.

• Management anticipates continued growth in sales of medical equipment, IT, and maintenance services, supported by higher public healthcare investment and an expanding product portfolio.

• Expansion in surgical robotics, especially in Poland and new markets such as Ukraine, is expected to drive future results.

• Recurring revenue from services and consumables is projected to increase due to a growing installed base and higher device utilization.